Skip to main content

Table 3 Self-reported psychological well-being, subjective cognitive complaints, depressive symptoms and level of fatigue

From: Impairment of cognitive functioning during Sunitinib or Sorafenib treatment in cancer patients: a cross sectional study

  Patients VEGFR TKI Patient controls Healthy controls
  Mean SD Mean SD Mean SD
SCL-90-R       
  Anxiety 13.07** 3.10 12.75* 3.06 11.10 1.71
  Depression 23.87*** 6.31 22.55** 5.32 18.20 2.68
  Sleep disturbance 4.93 2.57 5.00 2.03 4.10 1.40
  Agoraphobia 7.90 2.01 8.10 2.20 7.40 0.77
  Somatization 19.23*** 5.73 17.40* 6.07 14.17 3.18
  Cognitive-performance difficulty 14.77** 4.68 14.75** 4.82 11.43 2.13
  Interpersonal sensitivity and paranoid ideation 20.90 3.63 22.50 5.69 20.87 3.15
  Anger-hostility 6.90 1.27 6.90 1.12 6.43 0.86
  Total score 123.10*** 24.13 121.80** 26.81 103.67 11.88
CFQ       
  Total score 93.37 13.20 89.55 10.13 91.80 9.64
BDI-II       
  Total score 9.87*** 5.76 8.25** 5.78 3.60 2.98
CIS20r       
  Total score 67.67*** 26.75 61.05* 21.11 46.60 16.24
  1. Self-reported psychological well-being, subjective cognitive complaints, depressive symptoms and level of fatigue (mean + SD) for the patients using VEGFR TKI, the patient controls and the healthy controls. Post-hoc t-tests, patient groups compared to healthy controls: *P < 0.05, **P < 0.01, ***P < 0.001. Abbreviations: SCL-90-R Symptom Checklist-Revised, CFQ Cognitive Failures Questionnaire, BDI-II Beck Depression Inventory-Second Edition, CIS-20-R Checklist Individual Strength-Revised.